.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Novartis
Johnson and Johnson
Julphar
Cantor Fitzgerald
Healthtrust
Merck
Fish and Richardson
Chubb
Deloitte

Generated: September 26, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Polymer-based sustained release device
Abstract: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.
Inventor(s): Wright; Steven G. (Madeira, OH), Christenson; Troy (Mason, OH), Yeah; Thean Y. (Foxboro, MA), Rickey; Michael E. (Morrow, OH), Hotz; Joyce M. (Cincinnati, OH), Kumar; Rajesh (Marlborough, MA), Costantino; Henry R. (Woodinville, WA)
Assignee: Alkermes, Inc. (Cambridge, MA)
Application Number:11/104,877
Patent Claims: 1. A composition for sustained-release of exendin-4, consisting essentially of: a biocompatible polymer having dispersed therein about 3%-5% (w/w) exendin-4 and about 2% (w/w) sucrose, wherein the composition is free from additional ingredients that alter the rate of release of the exendin-4 from the composition.

2. A composition for sustained-release of a polypeptide, consisting of: a biocompatible polymer having dispersed therein about 5% (w/w) exendin-4 and about 2% (w/w) sucrose.

3. A composition for sustained-release of a polypeptide, consisting of: a biocompatible polymer having dispersed therein about 3%-5% (w/w) exendin-4 and about 2% (w/w) sucrose.

4. The composition of claim 1, wherein the biocompatible polymer is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s and blends and copolymers thereof.

5. The composition of claim 2, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

6. The composition of claim 3, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

7. The composition of claim 1, wherein the exendin-4 is present at about 5% (w/w) and the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

8. A composition for sustained-release of exendin-4, consisting essentially of: a biocompatible polymer having dispersed therein about 5% (w/w) exendin-4 and about 2% (w/w) sucrose, wherein the composition is free from additional ingredients that alter the rate of release of the exendin-4 from the composition.

9. The composition of claim 8, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1 and a molecular weight in the range of from about 45 to about 64 kDa.

10. The composition of claim 1, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

11. The composition of claim 1, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1 and a molecular weight in the range of from about 45 to about 64 kDa.

12. The composition of claim 2, wherein the biocompatible polymer is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s and blends and copolymers thereof.

13. The composition of claim 2, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1 and a molecular weight in the range of from about 45 to about 64 kDa.

14. The composition of claim 3, wherein the biocompatible polymer is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s and blends and copolymers thereof.

15. The composition of claim 3, wherein the exendin-4 is present at about 5% (w/w) and the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

16. The composition of claim 3, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1 and a molecular weight in the range of from about 45 to about 64 kDa.

17. The composition of claim 8, wherein the biocompatible polymer is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s and blends and copolymers thereof.

18. The composition of claim 8, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

19. A method of treating a patient having Type 2 diabetes comprising: administering a therapeutically effective amount of a sustained-release composition consisting essentially of a biocompatible polymer having dispersed therein about 3%-5% (w/w) exendin-4 and about 2% (w/w) sucrose, wherein the sustained-release composition is free from additional ingredients that alter the rate of release of the exendin-4 from the sustained-release composition.

20. The method of claim 19, wherein the exendin-4 is present at about 5% (w/w) and the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

21. The method of claim 19, wherein the sustained-release composition is administered by injection.

22. The method of claim 19, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

23. The method of claim 20, wherein the sustained-release composition is administered by injection.

24. A method of treating a patient having Type 2 diabetes comprising: administering a therapeutically effective amount of a sustained-release composition consisting of a biocompatible polymer having dispersed therein about 5% (w/w) exendin-4 and about 2% (w/w) sucrose.

25. The method of claim 24, wherein the biocompatible polymer is poly(lactide-co-glycolide) with a lactide:glycolide ratio of about 1:1.

26. The method of claim 24, wherein the sustained-release composition is administered by injection.

27. The method of claim 25, wherein the sustained-release composition is administered by injection.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Merck
Novartis
Citi
Express Scripts
Argus Health
Daiichi Sankyo
US Department of Justice
Boehringer Ingelheim
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot